PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan Applauds Affymetrix' Technology Legacy and Expansion into New Market Segments - Frost & Sullivan recognizes Affymetrix, Inc. with the 2011 North America Frost & Sullivan Product Leadership of the Year Award for its unwavering focus on enhancing its core microarray technology while remaining attentive to its customers' demands
Frost & Sullivan Applauds Affymetrix' Technology Legacy and Expansion into New Market Segments

 

NewswireToday - /newswire/ - Mountain View, CA, United States, 2011/03/17 - Frost & Sullivan recognizes Affymetrix, Inc. with the 2011 North America Frost & Sullivan Product Leadership of the Year Award for its unwavering focus on enhancing its core microarray technology while remaining attentive to its customers' demands.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Based on its recent analysis of the life science research tools market, Frost & Sullivan recognizes Affymetrix, Inc. with the 2011 North America Frost & Sullivan Product Leadership of the Year Award for its unwavering focus on enhancing its core microarray technology while remaining attentive to its customers' demands.

Of the 314 genomics researchers surveyed by Frost & Sullivan in late 2010, 94 percent are aware of Affymetrix and 61 percent are aware and have used the company's products. Of those aware of microarray technology in general (266 respondents), 59 percent selected Affymetrix as their preferred microarray supplier, while the next leading competitor polled only 11 percent. Meanwhile, 27 percent of respondents are ‘likely to adopt' microarrays in the next two years.

Microarrays are the preferred format for 60 percent of the 95 surveyed researchers conducting whole-genome gene expression profiling, 39 percent of the 61 surveyed researchers conducting whole-genome transcriptome analysis, and 38 percent of the 44 surveyed researchers conducting whole-genome copy number variation/loss of heterozygosity studies. Moreover, of the 59 respondents who selected translational research as their focus area, 47 percent selected microarray as the ‘best fit' technology, behind only qPCR/RT-PCR and high-throughput screening/analysis.

Staying true to its customer-centric policy, Affymetrix enhanced many aspects of its product offering over the last two years. The company introduced the GeneAtlas™ Personal Microarray System in 2010–a first-of-its-kind, affordable and easy-to-use solution that provides the robust capabilities of microarray technology to resource-limited or smaller laboratories. Moreover, the company launched its empowering Axiom™ Genotyping Solution and added two agricultural biotechnology arrays to its ever-expanding and market-leading portfolio of whole-transcript expression analysis arrays for human disease and model organism research. These products allow Affymetrix to maintain its dominance in the established areas of genomics research while addressing burgeoning market opportunities.

"For instance, in the area of gene expression, Affymetrix recently innovated its core gene expression microarray platform with a portfolio of whole-transcriptome arrays, becoming the only broad supplier of high-quality arrays for whole-transcript expression analysis, " said Frost & Sullivan Industry Manager Jonathan Witonsky. "The relevance of this technology is significant, especially in light of increasing next generation sequencing (NGS) utilization." Affymetrix has a strong reputation for providing a highly reliable and cost-effective solution for whole-transcript expression analysis; a solution that allows researchers to overcome the inaccuracies and the workflow, bioinformatic, and economic challenges that are still associated with whole-transcriptome ribonucleic acid (RNA) analysis by NGS."

Affymetrix's DNA and RNA microarray technologies are also widely used in clinical research applications to aid in the development of genetic tests for cancer, constitution cytogenetics and drug metabolism applications. Affymetrix is leading the way with its Powered by Affymetrix (PbA) program partners, who are developing an ever-expanding menu of clinical microarray tests on its Food and Drug Administration (FDA)-cleared instrumentation.

"Affymetrix also remains at the forefront of the genomic revolution by enabling clinical research that is designed to translate genomic discoveries into reliable clinical tools, " said Mr. Witonsky. "The company's successful diversification strategy into clinical research applications was most recently exemplified by the commercialization of its OncoScan™ FFPE Express cancer copy number array service."

"Whether being first to market with novel technologies or continually innovating established technologies, the company constantly reacts to market demand, " said Mr. Witonsky.

In response to receiving the award, Affymetrix President and Chief Executive Officer Kevin King said, "We are honored to receive the 2011 Frost and Sullivan Product Leadership of the Year Award as recognition for our ongoing commitment to our customers and the impact that our technologies continue to have in science and research. Looking forward, we are committed to remaining at the forefront of the genomic revolution with even more innovative technologies that provide unprecedented knowledge and ultimately life-improving solutions."

Each year, Frost & Sullivan presents this award to a company that has developed high-quality products that offer innovative features/functionalities that enhance customer value and find immediate acceptance in the market.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research in order to identify best practices in the industry.

About Affymetrix, Inc.

Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and nonprofit research institutes. More than 2,000 systems have been shipped around the world and almost 23,000 peer-reviewed papers have been published using the technology. Affymetrix (affymetrix.com) is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, Ohio and Singapore. The company has more than 900 employees worldwide and maintains sales and distribution operations across Europe and Asia.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Applauds Affymetrix' Technology Legacy and Expansion into New Market Segments

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Britni Myers 
210-477-8481 britni.myers[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Ipsen Announces Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow Ltd

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)